CONTEXT: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. OBJECTIVE: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. DESIGN: This was an open-label pilot study. SETTING: The setting was a tertiary care referral center. PATIENTS: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. INTERVENTION: Teriparatide was administered at 20 μg daily for 18 to 24 months. MAIN OUTCOME MEASURES: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. RESULTS: BMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P < .001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P < .02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm²/mm/y; P < .001) and higher serum IGF-1 (208 ± 54 vs 157± 44 ng/mL; P = .03). CONCLUSIONS: Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.
CONTEXT: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal cortical and trabecular bone microarchitecture. OBJECTIVE: The purpose of this study was to test the hypotheses that teriparatide increases bone mineral density (BMD) and bone formation and improves trabecular microarchitecture and stiffness in women with IOP. DESIGN: This was an open-label pilot study. SETTING: The setting was a tertiary care referral center. PATIENTS: Participants were 21 premenopausal women with unexplained fragility fractures or low BMD. INTERVENTION: Teriparatide was administered at 20 μg daily for 18 to 24 months. MAIN OUTCOME MEASURES: The primary endpoint was within-subject percent change in lumbar spine BMD. Secondary endpoints included percent change in hip and forearm BMD, transiliac biopsy parameters (trabecular bone volume, microarchitecture, stiffness, and adipocytes), serum N-terminal propeptide of procollagen type 1 (P1NP), and C-telopeptide. RESULTS: BMD increased at the spine (10.8 ± 8.3% [SD]), total hip (6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%) (all P < .001). Serum P1NP doubled by 1 month, peaked at 6 months, and returned to baseline by 18 to 24 months. Transiliac biopsies demonstrated significant increases in cortical width and porosity and trabecular bone volume and number increased, mirrored by a 71% increase in trabecular bone stiffness (P < .02-.001). Adipocyte area, perimeter, and volume/marrow volume decreased, with no change in adipocyte number. Four women had no increase in BMD and a blunted, delayed increase in serum P1NP. Nonresponders had markedly lower baseline bone formation rate (0.002 ± 0.001 vs 0.011 ± 0.006 mm²/mm/y; P < .001) and higher serum IGF-1 (208 ± 54 vs 157± 44 ng/mL; P = .03). CONCLUSIONS:Teriparatide was associated with increased spine and hip BMD and improved trabecular microarchitecture and stiffness at the iliac crest in the majority of women with IOP.
Authors: E Legrand; D Chappard; C Pascaretti; M Duquenne; S Krebs; V Rohmer; M F Basle; M Audran Journal: J Bone Miner Res Date: 2000-01 Impact factor: 6.741
Authors: D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay Journal: J Bone Miner Res Date: 2001-10 Impact factor: 6.741
Authors: R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak Journal: N Engl J Med Date: 2001-05-10 Impact factor: 91.245
Authors: Jean-Jacques Body; Gregory A Gaich; Wim H Scheele; Pandurang M Kulkarni; Paul D Miller; Anne Peretz; Robin K Dore; Ricardo Correa-Rotter; Alexandra Papaioannou; David C Cumming; Anthony B Hodsman Journal: J Clin Endocrinol Metab Date: 2002-10 Impact factor: 5.958
Authors: David W Dempster; Juliet E Compston; Marc K Drezner; Francis H Glorieux; John A Kanis; Hartmut Malluche; Pierre J Meunier; Susan M Ott; Robert R Recker; A Michael Parfitt Journal: J Bone Miner Res Date: 2013-01 Impact factor: 6.741
Authors: Kyle K Nishiyama; Adi Cohen; Polly Young; Ji Wang; Joan M Lappe; X Edward Guo; David W Dempster; Robert R Recker; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Adi Cohen; Stavroula Kousteni; Brygida Bisikirska; Jayesh G Shah; J Sanil Manavalan; Robert R Recker; Joan Lappe; David W Dempster; Hua Zhou; Donald J McMahon; Mariana Bucovsky; Mafo Kamanda-Kosseh; Julie Stubby; Elizabeth Shane Journal: J Bone Miner Res Date: 2017-03-23 Impact factor: 6.741